Putting Science to Work

In the News

  • India price advantage helped Boost Business

    NDTV- 22/11/2015. Peter Bains, director and CEO at Syngene International, told NDTV that it witnessed strong growth across its business verticals in the second quarter, which was supported by significant cost advantage in India.

  • Syngene Story

    ET-NOW - 03/10/2015. An exclusive interview with Kiran Mazumdar Shaw, Peter Bains and Manoj Nerurkar on Syngene's operations and journey so far at the sprawling Syngene campus.

  • Syngene eyes capacity and capability expansion post-IPO

    Outsourcing Pharma-21/10/2015. Syngene says it will invest in new capacity and capabilities, including a viral testing facility, as it reports strong results in its first quarter post-IPO.

  • Syngene Q2 net profit rises 31% to Rs 52 crore

    Economic Times- 20/10/2015 .Syngene International, research arm of Biocon, today posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ended September 30 .

  • Syngene share strength reflects India's contract research opportunity

    Times of India-15/09/2015 .Among the major India players, Syngene is the only pure CRO, and is estimated to have 40% of the market.

  • Syngene International Jumps 32% From Issue Price Within One Quarter

    CNBC TV18- 15/09/2015. "Syngene International is targeting a growth of USD 250 million by FY2018", says Peter Bains CEO of the company) .

  • CROs Are Making Headlines -India’s drug discovery service sector is heating up

    Contract Pharma-11/09/2015 .Syngene says it is intent on establishing new capabilities and augmenting existing services across the discovery & development continuum..

  • Syngene to spend $100 m on new plant at Mangalore SEZ

    Financial Express-29/08/2015 .Syngene is planning to set up a multi-product, multi-client contract manufacturing facility at Mangalore special economic zone (MSEZ) at an investment of $100 million (around Rs 660 crore).

  • Syngene International makes stellar debut, ends day up 24% over issue price

    Economic Times-11/08/2015 .It hit an intraday high of Rs 318.20 over its issue price, before settling the day at Rs 310.40,up 24.16 per cent on the BSE.

  • Syngene International, India’s first contract research organisation is all set to go for an IPO

    Business India - 23/06/2015 .Syngene International, India’s first contract research organisation is all set to go for an IPO.

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget